Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
Adams
G E
GE
Medical Research Council, Radiobiology Unit, Chilton, Didcot, Oxon, U.K.
Stratford
I J
IJ
Bremner
J C
JC
Edwards
H S
HS
Fielden
E M
EM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C067834:RB 6145; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole